Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,355,001 papers from all fields of science
Search
Sign In
Create Free Account
CBM-11
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
bromofosfamide
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2007
Review
2007
Design of new oxazaphosphorine anticancer drugs.
Jun Liang
,
Min Huang
,
W. Duan
,
Xue-Qing Yu
,
Shufeng Zhou
Current pharmaceutical design
2007
Corpus ID: 37225146
The oxazaphosphorines including cyclophosphamide (CPA, Cytoxan, or Neosar), ifosfamide (IFO, Ifex) and trofosfamide (Ixoten…
Expand
2001
2001
(S)-(−)-Bromofosfamide (CBM-11): synthesis and antitumor activity and toxicity in mice
K. Misiura
,
R. Kinas
,
Halina Kus´nierczyk
,
C. Radzikowski
,
W. Stec
Anti-Cancer Drugs
2001
Corpus ID: 9190298
(S)-(−)-Bromofosfamide (CBM-11), an enantiomerically pure bromo analog of ifosfamide, was found to be potent against several…
Expand
2001
2001
Pharmacokinetics of (-)-(S)-Bromofosfamide after Intravenous and Oral Administration in Mice
K. Kobylińska
,
M. Kobylińska
,
B. Sobik
Arzneimittelforschung
2001
Corpus ID: 45908078
Summary (-)-(S)-Bromofosfamide ((2S)-(2-chloro-ethylamino)-3-(2-bromoethyl)-1,3,2-oxa-zaphosphorinane 2-oxide, CAS 146452-37-1…
Expand
2001
2001
The antineoplastic CBM-11 shows activity against leukaemia, melanoma and lung cancer cells
2001
Corpus ID: 195137015
1999
1999
Synergistic antitumour effects of chemo-immunotherapy with an oxazaphosphorine drug and IL-2-secreting cells in a mouse colon cancer model
H. Kuśnierczyk
,
E. Pajtasz-Piasecka
,
C. Radzikowski
Medical Oncology
1999
Corpus ID: 42396645
The therapeutic efficacies of two chemical agents—cyclophosphamide (CY) and compound CBM-11—were compared in a chemo…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE
or Only Accept Required